Zobrazeno 1 - 10
of 192
pro vyhledávání: '"Joost van den Oord"'
Autor:
Emil Chteinberg, Julia Vogt, Julia Kolarova, Felix Bormann, Joost van den Oord, Ernst Jan Speel, Véronique Winnepenninckx, Anna Kordelia Kurz, Martin Zenke, Reiner Siebert, Axel zur Hausen
Publikováno v:
Epigenetics, Vol 15, Iss 12, Pp 1319-1324 (2020)
Merkel cell carcinoma (MCC) is a very rare, but highly aggressive skin cancer which occurs mainly in elderly patients. MCC cells show an expression pattern of three cell lineages: epithelial, neuroendocrine, and B-cell progenitor. This trilinear expr
Externí odkaz:
https://doaj.org/article/2d32c18c53b94996b47ca34144baa1d1
Autor:
Laura Gadeyne, Yannick Van Herck, Giorgia Milli, Zeynep Kalender Atak, Maddalena Maria Bolognesi, Jasper Wouters, Lukas Marcelis, Angeliki Minia, Vaia Pliaka, Jan Roznac, Leonidas G. Alexopoulos, Giorgio Cattoretti, Oliver Bechter, Joost Van Den Oord, Frederik De Smet, Asier Antoranz, Francesca Maria Bosisio
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The emergence of immune checkpoint inhibitors has dramatically changed the therapeutic landscape for patients with advanced melanoma. However, relatively low response rates and a high incidence of severe immune-related adverse events have prompted th
Externí odkaz:
https://doaj.org/article/206ab1bbe50a4eb19b7018688ac2ddd1
Autor:
Emil Chteinberg, Suzan Wetzels, Wouter Gerritsen, Lieve Temmerman, Joost van den Oord, Erik Biessen, Anna Kordelia Kurz, Véronique Winnepenninckx, Martin Zenke, Ernst-Jan Speel, Axel zur Hausen
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Merkel cell carcinoma (MCC) is a highly malignant skin cancer. Despite major treatment improvements during the last decade, up to 50% of patients do not respond to therapy or develop recurrent disease. For these patients, alternative trea
Externí odkaz:
https://doaj.org/article/b16ae6b01d8a4a70ac0deccedf5a266c
Autor:
Xiaoshuang Li, Panagiotis Karras, Raúl Torres, Florian Rambow, Joost van den Oord, Jean-Christophe Marine, Lidia Kos
Publikováno v:
Cell Reports, Vol 31, Iss 11, Pp 107765- (2020)
Summary: Tumor cell plasticity, including transdifferentiation, is thought to be a key driver of therapy failure, tumor dormancy, and metastatic dissemination. Although melanoma cells have been shown to adopt various phenotypic features in vitro, dir
Externí odkaz:
https://doaj.org/article/fed1826c9468410a914fcd79c4bb1c2c
Autor:
Francesca Maria Bosisio, Asier Antoranz, Yannick van Herck, Maddalena Maria Bolognesi, Lukas Marcelis, Clizia Chinello, Jasper Wouters, Fulvio Magni, Leonidas Alexopoulos, Marguerite Stas, Veerle Boecxstaens, Oliver Bechter, Giorgio Cattoretti, Joost van den Oord
Publikováno v:
eLife, Vol 9 (2020)
In melanoma, the lymphocytic infiltrate is a prognostic parameter classified morphologically into ‘brisk’, ‘non-brisk’ and ‘absent’ entailing a functional association that has never been proved. Recently, it has been shown that lymphocyti
Externí odkaz:
https://doaj.org/article/5f94f70b8b1b46cf85d03da3a1097f62
Autor:
Ali Talebi, Jonas Dehairs, Florian Rambow, Aljosja Rogiers, David Nittner, Rita Derua, Frank Vanderhoydonc, Joao A. G. Duarte, Francesca Bosisio, Kathleen Van den Eynde, Kris Nys, Mónica Vara Pérez, Patrizia Agostinis, Etienne Waelkens, Joost Van den Oord, Sarah-Maria Fendt, Jean-Christophe Marine, Johannes V. Swinnen
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
Melanoma patients harbouring BRAFV600E mutation generally develop resistance to targeted therapy. In this study, the authors demonstrate that SREBP-1-mediated induction of lipid biosynthesis contributes to therapy resistance in BRAF mutant melanoma.
Externí odkaz:
https://doaj.org/article/c1bb7bfd70be4f42827f1d7f1e16991f
Autor:
Canan Güvenç, Fien Neckebroeck, Asier Antoranz, Marjan Garmyn, Joost van den Oord, Francesca Maria Bosisio
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 19, p 10674 (2021)
Loss-of-function events in tumor suppressor genes (TSGs) contribute to the development and progression of cutaneous malignant melanoma (CMM). Epigenetic alterations are the major mechanisms of TSG inactivation, in particular, silencing by promoter Cp
Externí odkaz:
https://doaj.org/article/1f34d1507ae244ccb796c6351a722d55
Autor:
Canan Güvenç, Asier Antoranz, Anna Szumera-Ciećkiewicz, Pawel P. Teterycz, Piotr R. Rutkowski, Robert V. Rawson, Richard A. Scolyer, John F. Thompson, Julia Newton-Bishop, Marguerite Stas, Veerle Boecxstaens, Oliver Bechter, Jurgen Vercauteren, Marjan Garmyn, Joost van den Oord, Francesca Maria Bosisio
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 19, p 10568 (2021)
Cutaneous melanoma (CM) is the most aggressive form of skin cancer, and its worldwide incidence is rapidly increasing. Early stages can be successfully treated by surgery, but once metastasis has occurred, the prognosis is poor. However, some 5–10%
Externí odkaz:
https://doaj.org/article/5a8326c24f5542f486f40c137373da7c
Autor:
Lisa M. Hillen, Joost Van den Oord, Milan S. Geybels, Jürgen C. Becker, Axel zur Hausen, Véronique Winnepenninckx
Publikováno v:
Frontiers in Medicine, Vol 5 (2018)
Spitzoid neoplasms are a distinct group of melanocytic proliferations characterized by epithelioid and/ or spindle shaped melanocytes. Intermediate forms that share features of both benign Spitz nevi (SN) and Spitz melanoma, i.e., malignant Spitz tum
Externí odkaz:
https://doaj.org/article/e0cf1b216f4748b69776b8832148a7e3
Autor:
Eline Boons, Els Vanstreels, Maarten Jacquemyn, Tatiane C. Nogueira, Jasper E. Neggers, Thomas Vercruysse, Joost van den Oord, Sharon Tamir, Sharon Shacham, Yosef Landesman, Robert Snoeck, Christophe Pannecouque, Graciela Andrei, Dirk Daelemans
Publikováno v:
EBioMedicine, Vol 2, Iss 9, Pp 1102-1113 (2015)
Infection with HIV ultimately leads to advanced immunodeficiency resulting in an increased incidence of cancer. For example primary effusion lymphoma (PEL) is an aggressive non-Hodgkin lymphoma with very poor prognosis that typically affects HIV infe
Externí odkaz:
https://doaj.org/article/032494f4bfb3424aa0ed97a02a53817f